TSTickerStarGet alerts

Curis Reports Q3 2026 Net Loss of $8.1M with No Revenue

Curis reported a Q3 2026 net loss of $8.1 million or $1.94 per share, compared to a net loss of $7.7 million or $9.86 per share in Q3 2025; per-share loss improved year-over-year due to significantly higher share count from equity offerings. The company reported no revenue for the quarter due to the sale of Erivedge royalties to Oberland in Q4 2025, which generated $3.2 million in Q3 2025. Cash and cash equivalents totaled $5.0 million as of September 30, 2026, with the company expecting to fund operations into...

Share this story

Key takeaways

  • Net loss improved to $1.94 per share in Q3 2026 from $9.86 per share in Q3 2025, driven by increased share count from recent equity offerings rather than improved operations

  • No revenue reported in Q3 2026 versus $3.2 million in Q3 2025 due to sale of Erivedge royalty rights to Oberland in Q4 2025

  • R&D expenses decreased to $5.6 million from $6.4 million year-over-year, primarily due to lower employee-related costs partially offset by increased clinical costs

  • Cash position of $5.0 million as of September 30, 2026, extended to Q1 2027 runway with $7.5 million net proceeds from October 2026 private placement

  • TakeAim CLL study enrolled 12 patients with initial data expected in December 2026

  • TakeAim Lymphoma registrational study in PCNSL showed 100% ORR in BTKi-naïve patients and 33% ORR in BTKi-experienced patients as of July 2026

Key metrics

Net lossQ3 2026
$8.1 millionworsened from $7.7 million
Net loss per common share (basic and diluted)Q3 2026
$1.94improved from $9.86
Revenues, netQ3 2026
$0down from $3.2 million
Net loss (YTD)Nine months ended September 30, 2026
$40.9 millionworsened from $26.9 million
Net loss per common share (YTD, basic and diluted)Nine months ended September 30, 2026
$16.77improved from $43.82
Cash and cash equivalentsSeptember 30, 2026
$5.0 million
Research and development expensesQ3 2026
$5.6 milliondown from $6.4 million
General and administrative expensesQ3 2026
$3.2 milliondown from $3.7 million

Primary source

TickerStar generated this brief from an official company, investor-relations, earnings-call, or regulatory source. Review the primary material before making an investment decision.

Open SEC filing

Follow CRIS in real time

Get material earnings, filing, IR, and earnings-call alerts by email.

Create a free alert